Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | BMC Cancer

Figure 2

From: Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer

Figure 2

In vivo radiosensitizing effect of combined use of olaparib and PI-103. Bioluminescence imaging of nude mice implanted with MDA-MB-435S cells transfected with pGL4 luciferase reporter vector and treated with indicated drugs alone (upper left) or prior to irradiation (IR) (upper right) and quantitation (lower panels). A marked decrease in tumor volume was induced with combined use of olaparib and PI-103, compared to radiation alone (P < 0.001 by t-test). Means of ROI values were significantly different between groups (P < 0.001). Y-axes show bioluminescence in photons/second. P < 0.001, ***.

Back to article page